Konosuke Morimoto1, William J Janssen, Mayumi Terada. 1. Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. komorimo@nagasaki-u.ac.jp
Abstract
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia. The pathogenicity of IPF has been widely investigated but still remains to be clarified. Efferocytosis, the specialized recognition and ingestion of apoptotic cells by phagocytes, is essential for the resolution of inflammation in the lungs and repair of injured tissues. Impaired efferocytosis contributes to the pathogenesis of chronic lung diseases such as emphysema and cystic fibrosis. We hypothesized that efferocytosis would also be reduced in alveolar macrophages isolated from subjects with IPF. METHODS: Efferocytosis, was evaluated using Wright-Giemsa stained cell preparations isolated from the bronchoalveolar lavage (BAL) fluid of patients with IPF (n = 5), nonspecific interstitial pneumonitis (n = 6), cryptogenic organizing pneumonia (n = 4) and eosinophilic pneumonia (EP) (n = 5). RESULTS: Uningested apoptotic cells were significantly higher in BAL fluid from patients with IPF compared to other forms of interstitial lung disease. Macrophages isolated from patients with eosinophilic pneumonia had significantly fewer phagocytic ingestions than macrophages from the other three groups. CONCLUSION: Efferocytosis by alveolar macrophages was significantly lower in subjects with IPF compared to subjects with other interstitial pneumonia. Dysregulated efferocytosis may contribute to the pathogenesis of IPF.
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia. The pathogenicity of IPF has been widely investigated but still remains to be clarified. Efferocytosis, the specialized recognition and ingestion of apoptotic cells by phagocytes, is essential for the resolution of inflammation in the lungs and repair of injured tissues. Impaired efferocytosis contributes to the pathogenesis of chronic lung diseases such as emphysema and cystic fibrosis. We hypothesized that efferocytosis would also be reduced in alveolar macrophages isolated from subjects with IPF. METHODS: Efferocytosis, was evaluated using Wright-Giemsa stained cell preparations isolated from the bronchoalveolar lavage (BAL) fluid of patients with IPF (n = 5), nonspecific interstitial pneumonitis (n = 6), cryptogenic organizing pneumonia (n = 4) and eosinophilic pneumonia (EP) (n = 5). RESULTS: Uningested apoptotic cells were significantly higher in BAL fluid from patients with IPF compared to other forms of interstitial lung disease. Macrophages isolated from patients with eosinophilic pneumonia had significantly fewer phagocytic ingestions than macrophages from the other three groups. CONCLUSION: Efferocytosis by alveolar macrophages was significantly lower in subjects with IPF compared to subjects with other interstitial pneumonia. Dysregulated efferocytosis may contribute to the pathogenesis of IPF.
Authors: K Morimoto; H Amano; F Sonoda; M Baba; M Senba; H Yoshimine; H Yamamoto; T Ii; K Oishi; T Nagatake Journal: Am J Respir Cell Mol Biol Date: 2001-05 Impact factor: 6.914
Authors: Antje Prasse; Dmitri V Pechkovsky; Galen B Toews; Wolfgang Jungraithmayr; Florian Kollert; Torsten Goldmann; Ekkehard Vollmer; Joachim Müller-Quernheim; Gernot Zissel Journal: Am J Respir Crit Care Med Date: 2006-01-13 Impact factor: 21.405
Authors: Lynne A Murray; Rochelle L Argentieri; Francis X Farrell; Michelle Bracht; Hai Sheng; Brian Whitaker; Heena Beck; Ping Tsui; Karyn Cochlin; Holly L Evanoff; Cory M Hogaboam; Anuk M Das Journal: Int J Biochem Cell Biol Date: 2008-02-23 Impact factor: 5.085
Authors: C M Mermigkis; K Tsakanika; V Polychronopoulos; N Karagianidis; D Mermigkis; D Bouros Journal: Acta Cytol Date: 2001 Nov-Dec Impact factor: 2.319
Authors: Chris A Mares; Jyotika Sharma; Qun Li; Edward L Rangel; Elizabeth G Morris; Melissa I Enriquez; Judy M Teale Journal: Immunol Cell Biol Date: 2010-06-29 Impact factor: 5.126
Authors: R William Vandivier; Valerie A Fadok; Peter R Hoffmann; Donna L Bratton; Churee Penvari; Kevin K Brown; Joseph D Brain; Frank J Accurso; Peter M Henson Journal: J Clin Invest Date: 2002-03 Impact factor: 14.808
Authors: Lynne A Murray; Rogerio Rosada; Ana Paula Moreira; Amrita Joshi; Michael S Kramer; David P Hesson; Rochelle L Argentieri; Susan Mathai; Mridu Gulati; Erica L Herzog; Cory M Hogaboam Journal: PLoS One Date: 2010-03-12 Impact factor: 3.240
Authors: David K Scoville; Dianne Botta; Karen Galdanes; Stefanie C Schmuck; Collin C White; Patricia L Stapleton; Theo K Bammler; James W MacDonald; William A Altemeier; Michelle Hernandez; Steven R Kleeberger; Lung-Chi Chen; Terry Gordon; Terrance J Kavanagh Journal: FASEB J Date: 2017-07-17 Impact factor: 5.191
Authors: Erin J Plosa; John T Benjamin; Jennifer M Sucre; Peter M Gulleman; Linda A Gleaves; Wei Han; Seunghyi Kook; Vasiliy V Polosukhin; Scott M Haake; Susan H Guttentag; Lisa R Young; Ambra Pozzi; Timothy S Blackwell; Roy Zent Journal: JCI Insight Date: 2020-01-30
Authors: Benedikt Jäger; Benjamin Seeliger; Oliver Terwolbeck; Gregor Warnecke; Tobias Welte; Meike Müller; Christian Bode; Antje Prasse Journal: Front Immunol Date: 2021-04-23 Impact factor: 7.561
Authors: Gwenda F Vasse; Mehmet Nizamoglu; Irene H Heijink; Marco Schlepütz; Patrick van Rijn; Matthew J Thomas; Janette K Burgess; Barbro N Melgert Journal: J Pathol Date: 2021-03-03 Impact factor: 7.996